Senex Biotechnology Inc.
Maynard, MA Doing business as Senex Biotechnology Inc.
- UEI
- G8XKMW3DYMQ6
- CAGE
- 47JH9
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 10 Digital Wy, Maynard, MA 01754, USA
- Website
- senexbio.com
- Employees
- 1-10
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Nanoparticle formulation of mediator kinase inhibitor for the treatment of peritoneal ovarian cancer - metastatic… | National Cancer Institute | $800,000 | |
| Preventing in vivo resistance to PI3K/AKT/mtor inhibitors through mediator kinase inhibition - dysregulation of the… | National Cancer Institute | $800,000 | |
| Developing mediator kinase inhibitor for castration-refractory prostate cancer | Defense Health Agency | $1,050,000 | |
| Targeting CDK8 for the treatment of vein graft failure | National Heart Lung and Blood Institute | $299,151 | |
| CDK8/19 inhibitor for the treatment of HER2+ breast cancer | National Cancer Institute | $299,993 |
About Senex Biotechnology Inc.
Senex Biotechnology Inc. is a for-profit corporate entity registered in SAM.gov since November 2005, specializing in advanced biotechnology research and drug development focused on cancer therapeutics. The company appears to be a research-driven organization that develops innovative pharmaceutical interventions, particularly targeting complex cancer treatments through novel molecular approaches. Its primary focus seems to be on developing specialized drug formulations and inhibitor technologies that address challenging aspects of cancer treatment, with a particular emphasis on creating targeted therapies for hard-to-treat cancer subtypes.
The company has secured multiple significant federal grant awards from both civilian and defense agencies, primarily the National Cancer Institute and Defense Health Agency, totaling approximately $800,000 in research funding. These grants have supported sophisticated research projects in cancer treatment, including developing nanoparticle formulations for ovarian cancer metastases, investigating mechanisms to prevent drug resistance in PI3K/AKT/MTOR inhibitor treatments, and exploring mediator kinase inhibitors for castration-refractory prostate cancer. The grants, which are structured as Project Grants, demonstrate Senex Biotechnology's advanced scientific capabilities in creating innovative drug delivery mechanisms and exploring complex molecular interventions. Specifically, their research has involved developing stable nanoparticle formulations, analyzing pharmacokinetics, evaluating tumor suppression mechanisms, and conducting transcriptomic analyses to identify potential treatment markers across different cancer subtypes.
Quick answers
What is Senex Biotechnology Inc.'s UEI?
Senex Biotechnology Inc.'s Unique Entity ID (UEI) in SAM.gov is G8XKMW3DYMQ6.
What is Senex Biotechnology Inc.'s CAGE code?
Senex Biotechnology Inc.'s CAGE code is 47JH9.
What is Senex Biotechnology Inc.'s primary NAICS code?
Senex Biotechnology Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Senex Biotechnology Inc. located?
Senex Biotechnology Inc.'s physical address in SAM.gov is 10 Digital Wy, Maynard, MA 01754, USA.
Is Senex Biotechnology Inc. registered in SAM.gov?
Yes. Senex Biotechnology Inc.'s SAM.gov registration is active through August 27, 2027.
What is Senex Biotechnology Inc.'s most recent federal award?
Senex Biotechnology Inc.'s most recent federal grant award is Nanoparticle formulation of mediator kinase inhibitor for the treatment of peritoneal ovarian cancer - metastatic… (R41CA298223), from National Cancer Institute, on December 13, 2024.
On GovTribe
See Senex Biotechnology Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors